Summit Therapeutics is making strides with ivonescimab, but upcoming trial results and financial challenges suggest caution.

Data suggest that taletrectinib “provides clinically meaningful tumor shrinkage and prolonged disease control as a treatment option for advanced ROS1+ NSCLC, regardless of treatment history,” ...

Despite solid data, the lack of high-value indications and no unique platform makes Nuvalent's valuation seem inflated; I ...

The FDA is evaluating a new drug application for taletrectinib in patients with ROS1 fusion–positive non–small cell lung ...

A panelist discusses how first-line (1L) therapies, including EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib, are the standard of care for treating locally advanced or metastatic ...

Shares of Summit Therapeutics SMMT rose more than 15% on Friday after the analysts at Cantor Fitzgerald and Truist Securities ...

The phase II AURA trial compared osimertinib with chemotherapy in patients with T790M-positive NSCLC who had progressed ... whether the use of oral EGFR-TKI therapy alone is sufficient, or if ...

The big question is whether it can displace Tagrisso (osimertinib), like Lazcluze a third-generation EGFR TKI and AZ's top-selling ... with 80-85% of them having NSCLC. Of these, around 70% ...

Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). ivonescimab ...

T790M is an EGFR mutation seen in about two-thirds of all drug-resistant NSCLC cases. The mutation causes a change in the amino acids, which affects how someone will respond to therapy.